Free Trial
NASDAQ:IMMX

Immix Biopharma (IMMX) Stock Price, News & Analysis

Immix Biopharma logo
$2.06 -0.04 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 0.00 (0.00%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immix Biopharma Stock (NASDAQ:IMMX)

Advanced

Key Stats

Today's Range
$2.00
$2.22
50-Day Range
$1.96
$2.85
52-Week Range
$1.26
$3.20
Volume
211,379 shs
Average Volume
168,409 shs
Market Capitalization
$59.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Hold

Company Overview

Immix Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

IMMX MarketRank™: 

Immix Biopharma scored higher than 69% of companies evaluated by MarketBeat, and ranked 310th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immix Biopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Immix Biopharma has a consensus price target of $8.00, representing about 288.3% upside from its current price of $2.06.

  • Amount of Analyst Coverage

    Immix Biopharma has only been the subject of 3 research reports in the past 90 days.

  • Read more about Immix Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Immix Biopharma are expected to grow in the coming year, from ($0.87) to ($0.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immix Biopharma is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immix Biopharma is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immix Biopharma has a P/B Ratio of 4.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immix Biopharma's valuation and earnings.
  • Percentage of Shares Shorted

    2.81% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immix Biopharma has recently increased by 23.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Immix Biopharma does not currently pay a dividend.

  • Dividend Growth

    Immix Biopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.81% of the float of Immix Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Immix Biopharma has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Immix Biopharma has recently increased by 23.22%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Immix Biopharma has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Immix Biopharma this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for IMMX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immix Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,172.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    55.40% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 11.26% of the stock of Immix Biopharma is held by institutions.

  • Read more about Immix Biopharma's insider trading history.
Receive IMMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMMX Stock News Headlines

Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
See More Headlines

IMMX Stock Analysis - Frequently Asked Questions

Immix Biopharma's stock was trading at $2.20 at the beginning of the year. Since then, IMMX shares have decreased by 6.4% and is now trading at $2.06.

Immix Biopharma, Inc. (NASDAQ:IMMX) released its quarterly earnings data on Friday, August, 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.01.

Immix Biopharma (IMMX) raised $23 million in an IPO on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share.

Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE).

Company Calendar

Last Earnings
8/08/2025
Today
10/03/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMMX
CIK
1873835
Fax
N/A
Employees
9
Year Founded
2012

Price Target and Rating

High Price Target
$8.00
Low Price Target
$8.00
Potential Upside/Downside
+288.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$21.61 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-205.35%
Return on Assets
-110.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.23
Quick Ratio
1.23

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.48 per share
Price / Book
4.29

Miscellaneous

Outstanding Shares
28,834,000
Free Float
12,860,000
Market Cap
$59.40 million
Optionable
Optionable
Beta
0.23

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:IMMX) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners